Inactive Instrument

Ergomed

Equities

ERGO

GB00BN7ZCY67

Biotechnology & Medical Research

Ergomed plc Provides Earnings Guidance for the First Half of 2019 and Full Year Ending December 31, 2019

July 22, 2019 at 02:00 am EDT

Ergomed plc provided earnings guidance for the first half of 2019. For the period the company expects unaudited revenues to be approximately £35.0 million. The company expects both revenue and EBITDA for the year ending 31 December 2019 to be ahead of current market expectations.

Latest news about Ergomed

Ergomed Delists From London Stock Exchange	Nov. 14	MT
Permira Advisers Ltd. completed the acquisition of Ergomed plc from Amati Global Investors Ltd. and others.	Nov. 12	CI
Milton plans energy focus; Guild completes fund raise	Nov. 09	AN
UK Court Clears Permira's Ergomed Purchase	Nov. 09	MT
Ergomed says conditions satisfied for Permira takeover	23-10-27	AN
Permira's Takeover of Ergomed Nears Completion	23-10-27	MT
Ergomed's Takeover by Permira Advisers Expected to Take Effect mid-November	23-10-23	MT
Ergomed Shareholders Back Eden AcquisitionCo's Bid	23-10-13	MT
Ergomed plc acquired Panacea Pharma Projects Limited from Stuart Colligon.	23-10-09	CI
The FTSE 100 Closed Up as UK Retail Sales, Consumer Confidence Data Offers Economic Hope	23-09-22	DJ
Ergomed first-half profit firms ahead of agreed takeover by Permira	23-09-22	AN
Ergomed Posts Flat H1 Profit; Revenue Rises	23-09-22	MT
Earnings Flash (ERGO.L) ERGOMED Posts H1 Revenue GBP76.7M	23-09-22	MT
Ergomed plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-22	CI
FTSE 100 Closes Modestly Lower on Asia Caution	23-09-04	DJ
Stocks wilt after early promise with US closed	23-09-04	AN
British Land Shares Lack Drivers as City Valuations Dip	23-09-04	DJ
ANALYST RECOMMENDATIONS : Ergomed, Dollar general, Salesforce, Citigroup, Goldman Sachs...	23-09-04
AIM WINNERS & LOSERS: Physiomics brings in COO; Ergomed receives bid	23-09-04	AN
Ergomed agrees GBP700 million takeover by Permira	23-09-04	AN
Stocks lifted by hopes for US rate pause	23-09-04	AN
Ergomed Agrees GBP703 Million Takeover by Permira Funds	23-09-04	MT
CMC names new CFO; takeover offer for Ergomed	23-09-04	AN
Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc for approximately £700 million.	23-09-03	CI
FTSE 100 Closes Tuesday Up 0.2% Lifted by Unilever, Miners	23-07-25	DJ

Chart Ergomed

Duration

Period

More charts

Company Profile

Ergomed PLC is a United Kingdom-based company that is primarily focused on providing specialized services to the biopharmaceutical industry. The Company operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). Its CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. Its PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The Company serves over 100 countries. It operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Companies subsidiaries include PrimeVigilance Inc., PrimeVigilance USA Inc., PrimeVigilance s.r.o., PharmInvent regulatory s.r.o., PrimeVigilance Japan K.K., Haemostatix Limited and Sound Opinion Limited.

Sector

Biotechnology & Medical Research

Calendar

2024-09-23 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	111B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
BIONTECH SE	-12.15%	22.34B
ARGENX SE	-2.68%	21.93B
GENMAB A/S	-5.61%	18.59B
WUXI APPTEC CO., LTD.	-36.52%	18.12B
BEIGENE, LTD.	-10.09%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.7B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.45B

Bio Therapeutic Drugs